Pfizer Inc. / Esperion Therapeutics Inc.

Atherosclerotic Cardiovascular Disease (HDL-Targeted)

$25.0B Global statin/lipid market 2003 (Lipitor alone $9.2B)

Disease Overview

Atherosclerotic cardiovascular disease results from cholesterol-laden plaque accumulation in arterial walls, leading to myocardial infarction and stroke. By the early 2000s, statins (LDL-lowering) had become the cornerstone of prevention, and the next frontier was raising HDL ('good' cholesterol) and inducing direct plaque regression - the rationale behind Esperion's ApoA-I Milano program.

Competitive Landscape

In December 2003, the cardiovascular landscape was dominated by statins led by Pfizer's Lipitor (atorvastatin, $9.2B 2003 sales), Merck's Zocor (simvastatin), AstraZeneca's Crestor (rosuvastatin, just launched), and Bristol-Myers Squibb's Pravachol. The HDL-raising frontier was the next-generation hope: Pfizer was internally developing torcetrapib (CETP inhibitor), and Esperion's ETC-216 (recombinant ApoA-I Milano/phospholipid complex) had just published a 57-patient ACS Phase 2 in JAMA showing ~4% atheroma volume regression in 5 weeks of weekly infusions - a striking signal of direct plaque reversal not seen with statins. CIBC Oppenheimer's Mark Monane of Needham & Co. called the deal 'a glove fit' - Esperion provided unpartnered, mid-stage HDL assets complementing torcetrapib. Pfizer paid $35/share (54% premium) to lock up the HDL platform pre-emptively. Outcome: torcetrapib failed catastrophically in late 2006 (ILLUMINATE trial halted for excess mortality), and Pfizer subsequently terminated ETC-216 development; founder Roger Newton bought back rights in 2008 to relaunch Esperion around bempedoic acid (now Nexletol).